In summary, we have confirmed the ability of miR-23b and miR-218 antagonists to enter DM1 cells and enhance MBNL1 and MBNL2 mRNA levels, at concentrations well below their toxicity threshold. This evidence concerns the gene MBNL1 and myotonic dystrophy type 1.